R
Rentoceratib
Product
by Insilico Medicine
Rentoceratib is an investigational small-molecule medicine being developed for idiopathic pulmonary fibrosis (IPF). Public search results associate it with Insilico Medicine and describe it as a generative-AI-discovered candidate targeting TNIK; it is not an approved marketed product based on the available information.
What experts have said about Rentoceratib
2 statements · 2 positive
Insilico’s rentoceratib advanced to Phase 3 trials for idiopathic pulmonary fibrosis.
“rentoceratib has advanced to phase 3 trials in idiopathic pulmonary fibrosis”
Open the episode · Should we slow down AI progress? | MOONSHOTS #288Listen at 2:10:59
Insilico’s Phase 2a study showed three to four years of biological age reversal after four weeks.
“at week 4, they saw, according to these proteomic aging clocks, 3 to 4 years of biological age reversal.”
Open the episode · Should we slow down AI progress? | MOONSHOTS #288Listen at 2:13:19
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
